Biopsy results

How Often Is a Biopsy — Not Enough to Read?

Getting a result that says 'inadequate' or 'insufficient material' is one of the most frustrating outcomes in cancer diagnosis — you paid, you waited, and you still have no answer. The rate at which this happens depends more on the technique used than on chance.

Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed September 2026

Technique matters more than bad luck — Inadequacy is strongly linked to whether FNAC or core needle biopsy was used, and whether image guidance was involved.
Some sites are harder than others — Lung, deep lymph nodes, and pancreas have higher inadequacy rates regardless of technique.
Core biopsy gives more to work with — A core preserves tissue architecture, which FNAC cannot, and that changes both adequacy and what can be tested downstream.
One inadequate result is not the end — A repeat biopsy, or a different technique, often succeeds where the first attempt did not.

Book Free Consultation 1800 202 8726

4.8 · 800+ Google reviews · 15,000+ patients treated

17+

Cancer Specialists
on Panel

96.9%

Breast Cancer
Survival Rate*

15,000+

Patients
Treated

4.8★

Google Rating
(800+ reviews)

Inadequate biopsy results are more common with FNAC than with core needle biopsy. Rates vary by site and operator but are consistently higher when FNAC is used without image guidance or on hard-to-reach sites. ESMO and ASCO guidance favours core needle sampling for most solid tumours where tissue architecture affects the diagnosis.

How does adequacy compare across the three main biopsy techniques?

Feature	FNAC	Core Needle Biopsy	Surgical / Excision Biopsy
Material obtained	Cells only — no tissue architecture	Tissue core — architecture preserved	Largest sample — full architecture intact
Non-diagnostic rate	Higher — especially without image guidance	Lower — consistent across most sites	Very low — rarely non-diagnostic
Supports molecular testing	Limited — cytology alone rarely sufficient for full panel	Yes — IHC, PD-L1, NGS all possible	Yes — all downstream testing supported
Procedure setting	Outpatient, no anaesthetic, very quick	Outpatient, local anaesthetic	Procedure room or theatre; sedation or GA
Best suited for	Superficial, accessible lesions; rapid initial triage	Most solid tumours where architecture and markers matter	When core is non-diagnostic or lesion is very small
Main limitation	Insufficient material for subtyping or molecular markers	Small risk of bleeding or haematoma	More invasive; not always needed
Image guidance	Variable — often freehand for superficial sites	Recommended for most sites	Not applicable

Which biopsy sites have the highest inadequacy rates?

Lung lesions produce non-diagnostic results more often than most sites, particularly when the lesion is small, centrally located, or surrounded by collapsed tissue. CT-guided core biopsy reduces this substantially, but the site remains one of the most technically demanding.

Deep lymph nodes — in the chest, abdomen, or retroperitoneum — are harder to reach and more likely to yield insufficient material by FNAC. ESMO guidance recommends core needle biopsy for suspected lymphoma because cytology alone cannot reliably subtype the disease, and subtype directly determines treatment.

Thyroid nodules that are predominantly cystic, and tumours with a large necrotic centre, produce insufficient material more often regardless of technique. These are biological features of the lesion, not failures of the sampling procedure.

Meet the Specialists

17+ senior cancer specialists. One panel for your case.

Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.

Medical Oncologist

Dr. Naresh Gundu

MBBS, DNB (Internal Medicine), DM (Medical Oncology)

View Profile

Medical Oncologist

Dr. C. Raghavendra Reddy

MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)

View Profile

Medical Oncologist

Dr. Bharati Devi Gorantla

MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)

View Profile

Medical Oncologist

Dr. Owais Mohammed

MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)

View Profile

Medical Oncologist

Dr. T. Raghavender Reddy

MBBS, DM (Medical Oncology), MD (Radiation Oncology)

View Profile

Medical Oncologist

Dr. N. Kiranmayee

MBBS, DM (Medical Oncology), MD (Internal Medicine)

View Profile

Surgical Oncologist

Dr. Muralidhar Muddusetty

MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)

View Profile

Surgical Oncologist

Dr. Raghavendra Naik

MBBS, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile

Surgical Oncologist

Dr. Mohammed Imaduddin

M.B.B.S, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile

Surgical Oncologist

Dr. Vinay Mamidala

MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)

View Profile

Surgical Oncologist

Dr. Paila Gowri Naidu

MBBS, MS (General Surgery), M.Ch (Surgical Oncology), FMAS

View Profile

Radiation Oncologist

Dr. Venkata Sushma P

MBBS, MD (Radiation Oncology)

View Profile

Radiation Oncologist

Dr. Kirti Ranjan Mohanty

MBBS, MD (Radiation Oncology)

View Profile

Radiation Oncologist

Dr. Gangadhar Vajrala

MBBS, MD (Radiation Oncology), MPH

View Profile

Hematologist

Dr. Basudev Pokhrel

MBBS, M.D (Immunohematology & Blood Transfusion)

View Profile

Interventional Radiologist

Dr. Mohammed Imran

View Profile

Surgical Oncologist

Dr. Vajja Sandeep Kumar

MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology

View Profile

Surgical Oncologist

Dr. Sridhar Kamani

MBBS, MS (General Surgery), DrNB (Surgical Oncology)

View Profile

Want a specific doctor for your case? Mention them when booking.

Book Free Consultation

Get a straight answer from a specialist

45 minutes, your reports reviewed, your questions answered in plain language.

Book Free Consultation Call 1800 202 8726

When does core needle biopsy give a clearer answer than FNAC?

FNAC collects individual cells. Core needle biopsy takes a sliver of tissue where cells remain in their original arrangement. That arrangement — the architecture — is what a pathologist needs to tell invasive cancer from in-situ disease, and to subtype a lymphoma reliably.

For molecular testing — hormone receptors, HER2, PD-L1, or next-generation sequencing — tissue is almost always required. A cytology sample from FNAC is rarely sufficient for a full panel, and an incomplete panel delays or complicates treatment decisions.

If your FNAC was inadequate or inconclusive, asking your treating team whether a core needle biopsy is the right next step is a reasonable question. The answer depends on the site, what the team is still trying to establish, and whether image guidance was used the first time.

What else affects whether a biopsy gives enough material to read?

Image guidance: the single biggest factor in adequacy

Biopsies done under ultrasound or CT guidance consistently produce more adequate samples than those done freehand, because the radiologist can watch the needle entering the lesion in real time. For deep sites — chest, abdomen, retroperitoneum — image guidance is standard of care under ESMO and NCCN guidance. For superficial sites like breast or palpable lymph nodes, guidance still improves adequacy even when it is not always used.

Number of passes and on-site rapid assessment

Adequacy is sensitive to the number of times the needle enters the lesion and to operator experience at that specific site. More passes generally produce more material, up to a point. Some centres have on-site rapid assessment — a cytologist reviews the sample while you are still on the table — and can request an additional pass if the first is insufficient. Not all centres offer this; it is worth asking whether it is available before your procedure.

Lesion characteristics that make sampling harder

Very small lesions, lesions with a large necrotic centre, heavily fibrotic tumours, and predominantly cystic lesions all make adequate sampling harder. A necrotic core yields dead cells rather than viable tumour cells, which are insufficient for diagnosis. A fibrotic tumour may deflect the needle or yield connective tissue without diagnostic cells. These are facts about the tumour's biology — they are among the reasons a repeat biopsy at a different part of the lesion, or with a different technique, sometimes succeeds where the first attempt did not.

What 'inadequate' actually means on a pathology report

'Inadequate', 'non-diagnostic', 'insufficient material', and 'acellular' are variants of the same finding: the material received by the laboratory did not contain enough cells, or the right cells, to make a diagnosis. This is a pathology term describing the sample. It is not a comment on the seriousness of your condition, and it is not a judgement on the skill of the person who performed the biopsy. It means the question is still open, and the next step is a conversation with your treating doctor about how best to answer it.

Whether a repeat biopsy is needed — and who decides

Not every inadequate result leads automatically to a repeat biopsy. Your oncologist will weigh the clinical picture, imaging, any prior results, and what information is genuinely needed before recommending one. Sometimes imaging alone is sufficient to guide the next step. When a tissue diagnosis is essential — because treatment options depend on it — a repeat with a different technique or under image guidance is usually the right approach. That is a clinical decision that belongs with your treating team, not a routine protocol.

Explore 112 more Markers, Molecular Testing and Test Accuracy topics

Inadequate, Inconclusive & Repeat Biopsy

Breast Markers: ER, PR, HER2, Ki-67

False Negatives & Accuracy

IHC Markers Explained

Labs, Slides, Blocks & Second Opinions

Molecular & Genomic Testing

All Markers, Molecular Testing and Test Accuracy →

Next step

Still not sure what applies to you?

Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.

Book Free Consultation Call 1800 202 8726

Common questions

Frequently asked questions

How common is an inadequate biopsy result?

Published rates vary widely by technique, site, and whether image guidance was used — wide enough that quoting a single figure would be misleading. What is consistent in guidance from NCCN, ASCO, and ESMO is that FNAC produces non-diagnostic results more often than core needle biopsy at equivalent sites, and that the gap is largest at difficult sites like lung and deep lymph nodes. What matters for your situation is which technique was used and whether image guidance was involved — your team can explain both.

Does an inadequate biopsy mean the cancer is worse or harder to treat?

No. An inadequate biopsy result describes the sample, not the disease. It means the material collected was not enough to make a diagnosis — not that the cancer is more aggressive, more advanced, or harder to treat than if the biopsy had been adequate. Many people receive a clear diagnosis on a repeat biopsy with no change to their treatment options.

Why does lymphoma almost always need a core biopsy rather than FNAC?

Lymphoma is diagnosed partly by the arrangement of cells within the lymph node, not just by what individual cells look like. FNAC disrupts that arrangement because it removes cells without the surrounding tissue. A core needle biopsy takes a sliver of tissue where the architecture is intact, which allows the pathologist to subtype the lymphoma — for example, distinguishing Hodgkin from the many subtypes of non-Hodgkin lymphoma. Subtype directly determines treatment, so an FNAC showing abnormal lymphoid cells usually leads to core biopsy as the next step. ESMO lymphoma guidelines explicitly recommend core or excisional biopsy as the standard.

Will my insurance cover a repeat biopsy if the first one was inadequate?

Most health insurance policies in India cover repeat biopsies when the first result is non-diagnostic, but coverage terms vary by policy and insurer. Your hospital billing team can advise on the documentation needed and whether pre-authorisation is required. If you are paying out of pocket, ask for a cost estimate before the procedure — and ask whether the cost changes if image guidance is being added this time.

Can I go to a different hospital for the repeat biopsy?

Yes, and in some situations it is worth considering — particularly if the first biopsy was done without image guidance, or if the site requires a specialist technique such as endoscopic ultrasound. Bring the original biopsy report, any imaging, and the pathology slides if you have them, so the new team understands what was obtained and can plan the repeat accordingly. Your treating oncologist can advise on whether a different centre or technique is likely to improve the outcome.

What should I ask before having a repeat biopsy?

Ask why the first biopsy was inadequate, if the report does not explain it. Ask whether image guidance will be used this time if it was not before. Ask whether core needle biopsy is being recommended instead of FNAC, and why. Ask what the team expects to do with the result — specifically, whether the tissue obtained will be sufficient for the molecular testing that treatment decisions depend on. A clear answer to each of these helps you understand what the repeat is for and what it should achieve.

Full index